Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
NCT ID: NCT02995096
Last Updated: 2019-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23124 participants
OBSERVATIONAL
2016-01-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.
NCT06636409
Early Detection of de Novo Cancer in Liver Transplant Recipients
NCT05492617
Developing Prediction Models for Allograft Failure After Liver Transplantation
NCT05289609
Adult-to-Adult Living Donor Liver Transplantation Study
NCT00096733
Adult-to-Adult Living Donor Transplant Cohort Study
NCT01619475
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pre-treatment
Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
Sirolimus based immunosuppression
Immunosuppression regimens containing Sirolimus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hans-Christian Pommergaard, MD, PhD
Resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans-Christian Pommergaard, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dept. of Surgery and Transplantion, Rigshospitalet, Denmark
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
There is no unique protocol ID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.